J 2022

Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports

RIAD, Abanoub, Ave POLD, Elham KATEEB and Sameh ATTIA

Basic information

Original name

Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports

Authors

RIAD, Abanoub (818 Egypt, belonging to the institution), Ave POLD (203 Czech Republic), Elham KATEEB and Sameh ATTIA (guarantor)

Edition

Frontiers in Public Health, Lausanne, Frontiers, 2022, 2296-2565

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30304 Public and environmental health

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.200

RIV identification code

RIV/00216224:14110/22:00126236

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3389/fpubh.2022.952781

UT WoS

000830988400001

Keywords in English

anaphylaxis; COVID-19 vaccines; drug-related side effects and adverse reactions; oral manifestations; pharmacovigilance oral adverse events following COVID-19 vaccination 2

Tags

14110525, rivok

Tags

International impact, Reviewed
Změněno: 5/4/2023 08:16, Mgr. Tereza Miškechová

Abstract

V originále

Background: Oral adverse events (AEs) following COVID-19 vaccination have been sporadically reported during the previous months, warranting further investigation for their prevalence and suspected relationship with vaccine-elicited immune response. Methods: A retrospective analysis using the Vaccine Adverse Event Reporting System (VAERS) data was conducted to evaluate AEs within the oral cavity (mucosa, tongue, lips, palate, dentition, salivary glands) and AEs involving taste and other sensations. Oral AEs reported after receiving COVID-19 vaccination (test group) and seasonal influenza vaccination (control group) were extracted and cross-tabulated to assess their relative prevalence. Results: Among the 128 solicited (suspected) oral AEs, oral paresthesia (0.872%) was most reported after receiving COVID-19 vaccines, followed by the swelling of lips (0.844%), ageusia (0.722%), oral hypoesthesia (0.648%), swollen tongue (0.628%), and dysgeusia (0.617%). The reported prevalence of oral AEs was higher in the COVID-19 vaccine group than in the seasonal influenza group. The distribution pattern of the most reported oral AEs was similar for both COVID-19 and seasonal influenza vaccines. Female sex, older age (>39 years old), primer doses, and mRNA-based COVID-19 vaccines exhibited a higher reported prevalence of oral AEs. Conclusion: Within the limitations of this study, COVID-19 vaccines were found to be associated with rare oral AEs that are predominantly similar to those emerging following seasonal influenza vaccines. The most commonly reported oral AEs were oral paraesthesia (mouth-tingling), lip swelling, and ageusia, representing various pathophysiologic pathways that remain unclear. Taste-related AEs should be acknowledged in the context of the COVID-19 pandemic and the public should be adequately informed about a potential taste dysfunction after receiving the COVID-19 vaccination. Dentists and dental teams need to be aware of the prevalence, severity, and prognosis of oral AEs to inform their patients and increase public confidence in vaccines.

Links

EF19_073/0016943, research and development project
Name: Interní grantová agentura Masarykovy univerzity
MUNI/A/1402/2021, interní kód MU
Name: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu IV
Investor: Masaryk University
MUNI/IGA/1104/2021, interní kód MU
Name: COVID-19 Vaccines Safety Tracking in the Czech Republic (Acronym: CoVaST-CZ)
Investor: Masaryk University
Displayed: 9/11/2024 08:15